ScientiaLux
strataquest Glossary Immunohistochemistry
Staining Method

Immunohistochemistry

Chromogenic antibody staining for protein detection

View
Definition
Immunohistochemistry (IHC) uses the same antibody-based targeting as immunofluorescence but reveals the result with chromogenic dyes visible in brightfield rather than fluorescent labels. DAB (brown), Fast Red, or AP-Blue precipitate at the antibody binding site, creating a permanent stain that can be viewed with standard microscopes and preserved indefinitely. IHC is the workhorse of diagnostic pathology — the technology behind PD-L1 scoring, HER2 testing, and hundreds of other clinical biomarker assays.
Clinical Standard
The backbone of diagnostic pathology
Chromogenic Detection
Color precipitate at target site
Single Marker per Stain
Limited multiplexing in brightfield
Semi-Quantitative Scoring
Intensity and percentage

How It Works

IHC labels specific proteins with chromogenic dyes for brightfield detection:

  1. Tissue preparation — FFPE sections on charged slides. Antigen retrieval (heat-induced or enzyme-mediated) unmasks target epitopes.
  2. Primary antibody — Specific for the target protein. Applied at validated concentration and incubation time.
  3. Secondary detection — Enzyme-conjugated secondary antibody (HRP-anti-mouse, HRP-anti-rabbit) binds the primary. Polymer-based detection systems (no biotin) reduce background.
  4. Chromogen development — DAB substrate is applied. HRP catalyzes oxidation of DAB → insoluble brown precipitate at the antibody binding site. Development time controls intensity.
  5. Counterstain — Hematoxylin counterstains nuclei blue-purple for morphological context.
  6. Mounting and imaging — Permanent mounting medium, coverslip. Imaged in brightfield with whole-slide scanner or standard microscope.
Simplified

IHC uses antibodies to target specific proteins, then an enzyme reaction deposits a colored dye (usually brown DAB) at the binding site. Hematoxylin counterstains all nuclei blue. The result is a permanent stain visible with any standard microscope — brown where the target protein is present, blue for nuclei, and unstained (white) background.

Science Behind It

Contrast formation (Pawley): IHC produces absorption contrast — the chromogen deposit absorbs specific wavelengths. DAB absorbs primarily in the blue region (~400-500 nm), appearing brown (transmitted red + green). Hematoxylin absorbs red and green, appearing blue-purple. The combined absorption creates the characteristic two-color appearance of H-DAB staining. Color deconvolution exploits these known absorption profiles to separate the stains computationally.

Beer-Lambert in practice: DAB deposition follows the Beer-Lambert law in optical density space: OD_DAB = ε × c × l, where c is the local chromogen concentration and l is the section thickness. This linearity makes OD a valid measure of how much chromogen was deposited — and by extension, how much target antigen is present. However, the relationship between antigen amount and DAB deposit is complicated by: (1) enzyme kinetics (HRP saturation at high antigen density), (2) development time (longer = more deposit, nonlinearly), and (3) antibody penetration (may not reach all antigen in thick sections).

Why IHC is semi-quantitative: Unlike fluorescence (where intensity has a more direct relationship to fluorophore concentration), the enzymatic amplification in IHC introduces nonlinearities. A cell with twice as much antigen doesn't necessarily produce twice the DAB deposit — the enzyme reaction has kinetic limits. This is why pathologists use ordinal scales (0/1+/2+/3+) rather than continuous measurements, and why digital pathology improves reproducibility (measuring OD consistently) but doesn't fully solve the quantitative problem.

Simplified

IHC works by absorption — the brown DAB deposit blocks blue light, appearing brown in the brightfield image. Color deconvolution separates DAB from hematoxylin using their known absorption profiles. The enzyme amplification step makes IHC sensitive but also makes it non-linear — twice the target doesn't produce twice the stain, which is why scoring is semi-quantitative (0/1+/2+/3+) rather than truly quantitative.

Practical Example

PD-L1 IHC scoring for lung adenocarcinoma (22C3 pharmDx):

  1. FFPE section, 22C3 anti-PD-L1 antibody, DAB detection, hematoxylin counterstain
  2. Whole-slide scan at 20x
  3. Color Separation: hematoxylin + DAB channels
  4. Nuclei Detection on inverted hematoxylin → Grow for cytoplasm → Membrane Detection
  5. Tumor identification (CK+ or morphology-based)
  6. TPS = (PD-L1+ tumor cells / total tumor cells) × 100
  7. Clinical cutoffs: TPS ≥ 50% → first-line pembrolizumab; TPS 1-49% → pembrolizumab with chemotherapy
Simplified

PD-L1 IHC on lung cancer determines whether a patient receives immunotherapy. The Tumor Proportion Score (TPS) — percentage of tumor cells with membrane PD-L1 staining — is computed by detecting cells, measuring DAB intensity at the membrane, and applying the clinical cutoffs. Digital pathology makes this scoring reproducible and objective.

Connected Terms

Share This Term
Term Connections